Table 1 Immunohistochemical profile of both components of the tumor.
From: Post-radiation dedifferentiation of meningioma into osteosarcoma.
Immuno-marker | Clone* | Dilution | Pretreatment / Target retrieval | Meningioma component | Osteosarcoma component |
|---|---|---|---|---|---|
Vimentin | Vim 3B4 | 1:200 | Proteinase K enzyme 1:1 with TRIS buffer fro 4 min | Immunoreactive | Immunoreactive |
CD34 | QBEnd 10 | 1:25 | 10 mM citrate buffer, pH6 for 30 min with 20 min cool down | Non-immunoreactive | Non-immunoreactive |
Pan-cytokeratin | Polyclonal | 1:50 | Proteinase K enzyme 1:1 with TRIS buffer for 4 min | Non-immunoreactive | Non-immunoreactive |
S-100 protein | Polyclonal | 1:300 | Proteinase K enzyme 1:1 with TRIS buffer fro 4 min | Immunoreactive | Non-immunoreactive |
Estrogen receptor | ID5 | 1:75 | 10 mM citrate buffer, pH6 for 30 min with 20 min cool down | Non-immunoreactive | Non-immunoreactive |
Progesteron receptor | PgR636 | 1:50 | 10 mM citrate buffer, pH6 for 30 min with 20 min cool down. | Focally immunoreactive | Non-immunoreactive |
EMA | E29. (3). | 1:50 | No target retrieval | Immunoreactive | Non-immunoreactive |
Ki-67 | MIB-1 | 1:50 | 10 mM citrate buffer, pH6 for 30 min with 20 min cool down | 12% nuclei immunoreactive | 28% nuclei immunoreactive |